SAB Biotherapeutics Inc (SABS) — Cash Flow Reinvestment Rate
SAB Biotherapeutics Inc (SABS) has a Cash Flow Reinvestment Rate of 41.94x as of December 2022, reinvesting $9.09 Million (capex $117.75K plus investments $-8.97 Million) from operating cash flow of $216.72K. See SABS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
SAB Biotherapeutics Inc Cash Flow Reinvestment Rate (2020–2021)
Historical reinvestment intensity for SAB Biotherapeutics Inc across 2 annual periods. For the full cash flow conversion analysis, see SABS cash flow conversion.
Annual Cash Flow Reinvestment Rate for SAB Biotherapeutics Inc (2020–2021)
Year-by-year capital reinvestment analysis for SAB Biotherapeutics Inc. See SABS financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 11.02x | $21.89 Million | $1.99 Million | $10.94 Million | ▲ +333.0% |
| 2020 | 2.54x | $25.45 Million | $10.00 Million | $12.73 Million | — |